2.要約中間連結財務諸表及び主な注記
(1)要約中間連結財政状態計算書
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2024年3月31日) | | 当中間会計期間末 (2024年9月30日) |
資産 | | | | | |
流動資産 | | | | | |
現金及び現金同等物 | | | 58,094 | | 56,387 |
営業債権及びその他の債権 | | | 47,237 | | 43,071 |
棚卸資産 | | | 39,111 | | 42,805 |
その他の金融資産 | | | 10,609 | | 9,633 |
その他の流動資産 | | | 9,232 | | 7,929 |
流動資産合計 | | | 164,285 | | 159,826 |
非流動資産 | | | | | |
有形固定資産 | | | 33,582 | | 34,094 |
無形資産 | | | 25,120 | | 29,079 |
使用権資産 | | | 2,971 | | 2,615 |
その他の金融資産 | | | 32,862 | | 39,823 |
繰延税金資産 | | | 1,766 | | 274 |
その他の非流動資産 | | | 2,817 | | 2,829 |
非流動資産合計 | | | 99,119 | | 108,716 |
資産合計 | | | 263,404 | | 268,542 |
| | | | | |
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2024年3月31日) | | 当中間会計期間末 (2024年9月30日) |
負債及び資本 | | | | | |
負債 | | | | | |
流動負債 | | | | | |
営業債務及びその他の債務 | | | 24,706 | | 17,628 |
その他の金融負債 | | | 372 | | 286 |
リース負債 | | | 1,720 | | 1,317 |
未払法人所得税 | | | 3,594 | | 1,556 |
その他の流動負債 | | | 6,941 | | 6,923 |
流動負債合計 | | | 37,336 | | 27,712 |
非流動負債 | | | | | |
その他の金融負債 | | | 232 | | 233 |
リース負債 | | | 1,152 | | 1,234 |
退職給付に係る負債 | | | 4,090 | | 4,050 |
その他の非流動負債 | | | 58 | | 58 |
非流動負債合計 | | | 5,533 | | 5,578 |
負債合計 | | | 42,870 | | 33,290 |
資本 | | | | | |
資本金 | | | 5,174 | | 5,174 |
資本剰余金 | | | 4,445 | | 4,445 |
利益剰余金 | | | 198,260 | | 210,457 |
自己株式 | | | △2,480 | | △2,459 |
その他の資本の構成要素 | | | 14,825 | | 17,318 |
親会社の所有者に帰属する持分合計 | | | 220,224 | | 234,936 |
非支配持分 | | | 310 | | 315 |
資本合計 | | | 220,534 | | 235,252 |
負債及び資本合計 | | | 263,404 | | 268,542 |
E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第7号参考様式 [IFRS](連結)(一般2Q)IFRStrueCTE2024-04-012024-09-30Q22025-03-312023-04-012023-09-302024-03-311falsefalsefalse451602023-04-012023-09-30jpcrp_cor:ReportableSegmentsMember451602023-04-012023-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602023-04-012023-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602023-04-012023-09-30jpcrp_cor:ReconcilingItemsMember451602024-04-012024-09-30jpcrp_cor:ReportableSegmentsMember451602024-04-012024-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602024-04-012024-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602024-04-012024-09-30jpcrp_cor:ReconcilingItemsMember451602023-03-31451602024-03-31451602023-04-012023-09-30451602023-09-30451602024-04-012024-09-30451602024-09-30451602024-11-13451602023-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-03-31jpigp_cor:ShareCapitalIFRSMember451602023-03-31jpigp_cor:CapitalSurplusIFRSMember451602023-03-31jpigp_cor:RetainedEarningsIFRSMember451602023-03-31jpigp_cor:TreasurySharesIFRSMember451602023-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012024-09-30jpigp_cor:NonControllingInterestsIFRSMember451602024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-09-30jpigp_cor:ShareCapitalIFRSMember451602024-09-30jpigp_cor:CapitalSurplusIFRSMember451602024-09-30jpigp_cor:RetainedEarningsIFRSMember451602024-09-30jpigp_cor:TreasurySharesIFRSMember451602024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-09-30jpigp_cor:NonControllingInterestsIFRSMember451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012023-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-04-012023-09-30jpigp_cor:ShareCapitalIFRSMember451602023-04-012023-09-30jpigp_cor:CapitalSurplusIFRSMember451602023-04-012023-09-30jpigp_cor:RetainedEarningsIFRSMember451602023-04-012023-09-30jpigp_cor:TreasurySharesIFRSMember451602023-04-012023-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-04-012023-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-04-012023-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-04-012023-09-30jpigp_cor:NonControllingInterestsIFRSMember451602023-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-09-30jpigp_cor:ShareCapitalIFRSMember451602023-09-30jpigp_cor:CapitalSurplusIFRSMember451602023-09-30jpigp_cor:RetainedEarningsIFRSMember451602023-09-30jpigp_cor:TreasurySharesIFRSMember451602023-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-09-30jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012024-09-30jpigp_cor:ShareCapitalIFRSMember451602024-04-012024-09-30jpigp_cor:CapitalSurplusIFRSMember451602024-04-012024-09-30jpigp_cor:RetainedEarningsIFRSMember451602024-04-012024-09-30jpigp_cor:TreasurySharesIFRSMember451602024-04-012024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure